The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.
February 18th 2025
The FDA approved Ospomyv and Xbryk, denosumab biosimilars that could expand access to treatment for osteoporosis, cancer-related bone loss, and other endocrine diseases.
AAM Report: Generics and Biosimilars Generate $408 Billion in 2022
Laura Wingate: Biosimilars Can Improve Access to Treatment for Patients